Chippenham, UK – 9 December 2015: Vectura Group plc (LSE: VEC; “Vectura” or the “Company”), confirms the commencement by Novartis of the first Phase III trial of QVM149, a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medication. Enrolment of the first patients into the trial programme will now trigger the receipt of a milestone payment to Vectura of $3.75m under the terms of the Licence Agreement.
QVM149 is a fixed dose, once daily combination of the long-acting beta2-agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the inhaled corticosteroid (ICS) mometasone fuorate.
Glycopyrronium bromide was licensed exclusively to Novartis in April 2005 by Vectura and its co-development partner Sosei.
First regulatory filings of QVM149 are planned for 2018.
Ends –
Enquiries
Vectura Group plc
+44 (0)1249 667700
Karl Keegan, Chief Corporate Development Officer
Fleur Wood, Director – Investor Relations & Corporate Communications
Citigate Dewe Rogerson
+44 (0)20 7638 9571
David Dible / Mark Swallow
About Vectura
Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth $44 billion worldwide.[1]
Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.
Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy.
For further information, please visit Vectura’s website at www.vectura.com.
